BR0101264A - Derivados de diazepan ou seus sais - Google Patents

Derivados de diazepan ou seus sais

Info

Publication number
BR0101264A
BR0101264A BR0101264-9A BR0101264A BR0101264A BR 0101264 A BR0101264 A BR 0101264A BR 0101264 A BR0101264 A BR 0101264A BR 0101264 A BR0101264 A BR 0101264A
Authority
BR
Brazil
Prior art keywords
diazepan
salts
derivatives
anticoagulant
emboli
Prior art date
Application number
BR0101264-9A
Other languages
English (en)
Inventor
Fukushi Hirayama
Hiroyuki Koshio
Tsukasa Ishihara
Norio Seki
Shunichiro Hachiya
Keizo Sugasawa
Ryota Shiraki
Yuji Koga
Takeshi Shigenaga
Yuzo Matsumoto
Souichirou Kawazoe
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18611560&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0101264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of BR0101264A publication Critical patent/BR0101264A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Patente de Invenção: "DERIVADOS DE DIAZEPAN OU SEUS SAIS". Para fornecer um composto que apresenta uma ação anticoagulante com base na inibição do fator X de coagulação sang³ínea ativada e que é útil como um anticoagulante ou como um agente para a prevenção e tratamento de doenças causadas por trombos ou êmbolos. Um derivado de diazepan, tal como a 3-hidróxi-4'-metóxí-2-{[4(4-metil-1,4-diazepan-1-il)benzoil]amino}benz anilida, ou um sal do mesmo é um ingrediente efetivo.
BR0101264-9A 2000-03-31 2001-03-30 Derivados de diazepan ou seus sais BR0101264A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000096858 2000-03-31

Publications (1)

Publication Number Publication Date
BR0101264A true BR0101264A (pt) 2001-11-06

Family

ID=18611560

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101264-9A BR0101264A (pt) 2000-03-31 2001-03-30 Derivados de diazepan ou seus sais

Country Status (21)

Country Link
US (3) US6642224B1 (pt)
EP (2) EP1415990B1 (pt)
JP (1) JP3788349B2 (pt)
KR (1) KR100739359B1 (pt)
CN (1) CN1226292C (pt)
AR (1) AR027985A1 (pt)
AT (2) ATE340166T1 (pt)
AU (2) AU776053B2 (pt)
BR (1) BR0101264A (pt)
CA (1) CA2395846C (pt)
DE (2) DE60103390T2 (pt)
DK (1) DK1273575T3 (pt)
ES (2) ES2217129T3 (pt)
HU (1) HUP0101333A3 (pt)
MX (1) MXPA01003279A (pt)
PL (1) PL207651B1 (pt)
PT (1) PT1273575E (pt)
RU (1) RU2257381C2 (pt)
TR (1) TR200401955T4 (pt)
TW (1) TW575569B (pt)
WO (1) WO2001074791A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
ATE374765T1 (de) 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
RU2276137C2 (ru) * 2000-11-22 2006-05-10 Астеллас Фарма Инк. Замещенные производные бензола или их соли, фармацевтическая композиция на их основе
AU2001297648A1 (en) 2000-11-28 2002-08-28 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003050088A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2004110433A1 (de) * 2003-06-18 2004-12-23 Merck Patent Gmbh Pyrrolidin-1, 2- dicarbonsäure- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen
EP1670783A2 (en) 2003-09-30 2006-06-21 Eli Lilly And Company Antithrombotic aromatic ethers
DE602005019316D1 (en) 2004-11-24 2010-03-25 Lilly Co Eli Aromatische etherderivate als thrombin-hemmer
DE602005016297D1 (de) 2004-11-29 2009-10-08 Lilly Co Eli Antithrombotische diamide
JP4900238B2 (ja) 2005-02-02 2012-03-21 味の素株式会社 新規ベンズアミジン化合物
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
TW200734304A (en) 2005-11-08 2007-09-16 Astellas Pharma Inc Benzene derivative or salt thereof
ES2382055T3 (es) 2006-11-02 2012-06-04 Millennium Pharmaceuticals, Inc. Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa
JP2010120852A (ja) * 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
EP2311810A4 (en) 2008-07-11 2012-04-04 Ajinomoto Kk AMIDINE DERIVATIVE
TW201021832A (en) * 2008-09-30 2010-06-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
JP5827327B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
US20130261130A1 (en) * 2010-11-01 2013-10-03 Shaheen Ahmed Neurotrypsin inhibitors
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417200A (en) * 1994-01-25 1995-05-23 Wasielewski; John J. Lantern cooker
PT798295E (pt) 1994-12-02 2003-07-31 Yamanouchi Pharma Co Ltd Novo derivado de amidinonaftilo ou sal deste
CA2294042A1 (en) 1997-06-26 1999-01-07 David Kent Herron Antithrombotic agents
EP0999834B1 (en) 1997-06-26 2005-10-12 Eli Lilly And Company Antithrombotic agents
JP2002510313A (ja) 1997-06-26 2002-04-02 イーライ・リリー・アンド・カンパニー 抗血栓物質
DE69830504T2 (de) 1997-06-26 2006-03-16 Eli Lilly And Co., Indianapolis Antithrombotische mitteln
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
IL135536A0 (en) 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
WO2000039118A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
EP1140905B1 (en) 1998-12-23 2003-05-14 Eli Lilly And Company Heteroaromatic amides as inhibitor of factor xa
US6610704B1 (en) 1998-12-23 2003-08-26 Eli Lilly And Company Antithrombotic amides
JP4390024B2 (ja) * 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
RU2002110295A (ru) 1999-09-17 2003-12-10 Милленниум Фармасьютикалс, Инк. (Us) Ингибиторы фактора Ха
NZ517829A (en) 1999-09-17 2004-12-24 Millennium Pharm Inc Benzamides and related inhibitors of factor Xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
ATE374765T1 (de) * 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
AU2001297648A1 (en) * 2000-11-28 2002-08-28 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa

Also Published As

Publication number Publication date
PL207651B1 (pl) 2011-01-31
RU2257381C2 (ru) 2005-07-27
ES2271464T3 (es) 2007-04-16
HU0101333D0 (en) 2001-06-28
PT1273575E (pt) 2004-09-30
CN1226292C (zh) 2005-11-09
US20040068109A1 (en) 2004-04-08
US20030195193A1 (en) 2003-10-16
AU2001244634A1 (en) 2001-10-15
CN1319594A (zh) 2001-10-31
HUP0101333A2 (hu) 2002-02-28
DE60123294D1 (de) 2006-11-02
DE60123294T2 (de) 2007-04-05
ATE340166T1 (de) 2006-10-15
USRE43481E1 (en) 2012-06-19
PL346731A1 (en) 2001-10-08
EP1273575A1 (en) 2003-01-08
KR100739359B1 (ko) 2007-07-18
MXPA01003279A (es) 2004-07-30
DE60103390D1 (de) 2004-06-24
TW575569B (en) 2004-02-11
CA2395846A1 (en) 2001-10-11
US6642224B1 (en) 2003-11-04
US7307074B2 (en) 2007-12-11
EP1415990B1 (en) 2006-09-20
WO2001074791A1 (fr) 2001-10-11
KR20010095174A (ko) 2001-11-03
EP1415990A1 (en) 2004-05-06
AU776053B2 (en) 2004-08-26
TR200401955T4 (tr) 2004-09-21
AU2982701A (en) 2001-10-04
DE60103390T2 (de) 2005-06-16
EP1273575A4 (en) 2003-01-08
ES2217129T3 (es) 2004-11-01
JP3788349B2 (ja) 2006-06-21
ATE267178T1 (de) 2004-06-15
CA2395846C (en) 2009-08-11
AR027985A1 (es) 2003-04-23
EP1273575B1 (en) 2004-05-19
DK1273575T3 (da) 2004-09-13
HUP0101333A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
BR0101264A (pt) Derivados de diazepan ou seus sais
AU2406402A (en) Substituted benzene derivatives or salts thereof
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
PT1295890E (pt) Novos derivados de pirazina ou os seus sais, composicoes farmaceuticas que os contem, e compostos intermedios utilizados na sua producao
CO5550436A2 (es) Derivados de benzamida
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
ES2196527T3 (es) Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
ES2120132T3 (es) Aductos de bisulfito de argininaldehidos utiles como inhibidores de la trombina y anticoagulantes.
BR9908474A (pt) Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
HRP20040758B1 (hr) Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
BR0308796A (pt) Derivados de benzofurano
BR0010802A (pt) Antagonistas de receptor il-8
BR9814983A (pt) Derivado de bifenil-amidina, pró-medicamento; inibidor de coagulação sanguìnea, e, agentes profilático e terapêutico para trombose ou êmbolo.
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DOP2001000268A (es) Derivados puente de piperazina
BR0110913A (pt) Método de administrar um bisfosfonato

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.